How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.01. During the same quarter in the prior year, the firm earned ($0.51) EPS.

What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?

12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com . Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rubius Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE) , Marinus Pharmaceuticals (MRNS) , Xeris Biopharma (XERS) , Fulcrum Therapeutics (FULC) , Recro Pharma (REPH) , TG Therapeutics (TGTX) , Tilray (TLRY) , Viking Therapeutics (VKTX) , ADMA Biologics (ADMA) and Adverum Biotechnologies (ADVM) .

When did Rubius Therapeutics IPO?

Rubius Therapeutics (RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

NASDAQ:RUBY

Rubius Therapeutics (RUBY) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free RUBY Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.06
▼
$0.06
50-Day Range: $0.02
▼
$0.06
52-Week Range: $0.00
▼
$0.38

Volume: 755,800 shs
Average Volume: 1.15 million shs
Market Capitalization: $5.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Insider Trades Social Media Sustainability

Get Rubius Therapeutics alerts:

Ad InvestorPlace

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

Go here now for this breaking story.

About Rubius Therapeutics Stock (NASDAQ:RUBY)

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

Ad InvestorPlace

The Next Nvidia?

Go here now for this breaking story.

RUBY Stock News Headlines

March 11, 2024 | bizjournals.com

Vacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'

November 5, 2023 | morningstar.com

Rubius Therapeutics Inc RUBY

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

August 2, 2023 | uk.finance.yahoo.com

RUBY - Rubius Therapeutics, Inc.

July 25, 2023 | morningstar.com

North American Morning Briefing: Alphabet, -2-

March 2, 2023 | finance.yahoo.com

Rubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On Alternatives

February 14, 2023 | marketwatch.com

Thinking about buying stock in Sorrento Therapeutics, Rubius Therapeutics, Ideanomics, SoundHound AI, or C3.ai?

February 14, 2023 | msn.com

Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

January 25, 2023 | yahoo.com

The Wrap: Ruby's moving to Congress Street, launching new French concept

January 12, 2023 | mirror.co.uk

Ruby Wax sparks concern from fans after posting video from hospital bed

January 12, 2023 | dailymail.co.uk

Ruby Wax sparks concern amongst fans with her latest appearance from a hospital bed promoting book

November 18, 2022 | finance.yahoo.com

Former Rubius CEO jumps to another Flagship spinout

November 4, 2022 | finance.yahoo.com

Rubius Therapeutics lays off most of its staff, explores sale

November 3, 2022 | finance.yahoo.com

Rubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic Alternatives

November 2, 2022 | seekingalpha.com

Rubius stock falls over 5% after hours on strategic review, more job cuts

November 2, 2022 | finance.yahoo.com

Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

October 28, 2022 | finance.yahoo.com

Rubius Therapeutics, Inc. (RUBY)

October 10, 2022 | reuters.com

Rubius Therapeutics Inc

September 19, 2022 | bizjournals.com

Flagship-backed Vesalius lays off 43%

September 19, 2022 | finance.yahoo.com

Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

September 14, 2022 | bizjournals.com

Rubius Therapeutics lays off 75% of staff, looks to sell Smithfield facility

September 13, 2022 | finance.yahoo.com

Rubius Therapeutics scraps platform, lays off 160

September 13, 2022 | finance.yahoo.com

Rubius Therapeutics Shifts Its Clinical Focus, Pulls Plug On Two Early-Stage Cancer Assets

September 13, 2022 | seekingalpha.com

Rubius stock slumps 26% as tumor trials of RTX-240, RTX-224 axed, cuts 75% workforce

September 13, 2022 | nasdaq.com

Rubius To Discontinue Clinical Trials Of RTX-240, RTX-224 - Quick Facts

September 13, 2022 | finance.yahoo.com

Rubius Therapeutics Announces Strategic Update

See More Headlines

Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:RUBY
CUSIP: N/A
CIK: 1709401
Web: www.rubiustx.com
Phone: (508) 543-1720
Fax: N/A
Employees: 6
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.17 per share
Price / Book: 0.34

Miscellaneous

Outstanding Shares: 90,480,000
Free Float: 85,687,000
Market Cap: $5.16 million
Optionable: Not Optionable
Beta: 2.59

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Laurence A. Turka M.D. (Age 66)
Chief Scientific Officer and Head of Research & Translational Medicine
Comp: $626.55k
Mr. Craig R. Jalbert CIRA (Age 62)
President, Treasurer, CS, Principal Exe Officer, Interim Principal Fin. & Acc. Off. and Director
Ms. Marissa Hanify
Director of Corporate Communications

Key Competitors

View All Competitors

RUBY Stock Analysis - Frequently Asked Questions

How were Rubius Therapeutics' earnings last quarter?: Rubius Therapeutics, Inc. (NASDAQ:RUBY) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.01. During the same quarter in the prior year, the firm earned ($0.51) EPS.
What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?: 12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Rubius Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Marinus Pharmaceuticals (MRNS), Xeris Biopharma (XERS), Fulcrum Therapeutics (FULC), Recro Pharma (REPH), TG Therapeutics (TGTX), Tilray (TLRY), Viking Therapeutics (VKTX), ADMA Biologics (ADMA) and Adverum Biotechnologies (ADVM).
When did Rubius Therapeutics IPO?: Rubius Therapeutics (RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

This page (NASDAQ:RUBY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Rubius Therapeutics (RUBY) Stock Price, News & Analysis

About Rubius Therapeutics Stock (NASDAQ:RUBY)

RUBY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

RUBY Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info